Latest News

NEW YORK – Hoth Therapeutics, Inc. (NASDAQ: HOTH) a patient-focused clinical-stage biopharmaceutical company, announced it submitted an Orphan Drug Designation Request to the US Food and Drug Administration (FDA) for HT-KIT for the treatment of mastocytosis. HT-KIT is an antisense oligonucleotide that targets the proto-oncogene cKIT by inducing mRNA frameshifting, resulting in the...
NEW YORK – Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has executed an agreement with REPROCELL Ltd., a contract research organization (CRO), providing a unique combination of products and services to power translational research, to assess the effect of the HT-003 therapeutic platform on tissue from ulcerative colitis and Crohn’s disease patients. Fresh...
WASHINGTON — The Global Fund to Fight AIDS, Tuberculosis, and Malaria is currently facing a major financing shortfall. While the Foreign Operations subcommittee provided a welcome increase over the President’s request, today’s markup suggests that the U.S. is going to fall far short of its commitment to fund fully its...
L-Asparaginase is one of the key drugs used to treat children with acute lymphoblastic leukemia (ALL). However, some children fail to achieve therapeutic levels of L-asparaginase after receiving the drug. The mechanisms underlying such therapeutic failure are not well defined. But now, Vaskar Saha and colleagues, at the Paterson Institute...
Cambridge, Mass. – A rare but potent genetic mutation that alters a protein in the brain’s immune cells, known as microglia, can give people as much as a three-fold greater risk of developing Alzheimer’s disease. A new study by researchers in The Picower Institute for Learning and Memory at MIT...
NEW YORK – A Ludwig Cancer Research study has found that the circadian clock—which synchronizes physiological and cellular activities with the day-night cycle and is generally thought to be tumor suppressive—in fact has a contextually variable role in cancer. “A lot of evidence suggests that the biological clock is broken...
Collectively rare diseases are anything but rare – they impact 30 million people in the US and ten times that amount globally. And 1 in 3 children suffering from a rare disease will not survive beyond the age of five. One of the biggest challenges facing clinicians is making a...